Current Hematologic Malignancy Reports

, Volume 2, Issue 3, pp 143–150 | Cite as

Late effects of therapy for Hodgkin’s lymphoma

  • Michael Jacob Adams
  • Louis S. Constine
  • Steven E. Lipshultz
Article

Abstract

Hodgkin’s lymphoma exemplifies a malignancy in which the benefits and risks of therapy are strikingly obvious: although 70% to 95% of patients survive (depending on disease stage), the late adverse health effects of therapy compromise quality of life and can be fatal. We review the broad range of these potential effects. Although secondary malignancies and cardiovascular disease are the most life-threatening sequelae, pulmonary, endocrine, and reproductive effects can also substantially compromise quality of life. Specific sequelae are not distributed evenly among survivors but depend on characteristics of the patient and treatment. Recent risk-adapted treatment protocols have eliminated or reduced the use of therapies most associated with adverse effects, such as alkylating agents, anthracyclines, and radiotherapy. Early studies suggest that these strategies reduce the frequency and severity of adverse effects, but additional follow-up of patients is necessary to confirm improved outcomes. Recognition of adverse effects has also led to recommendations for screening.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References and Recommended Reading

  1. 1.
    Ries LAG, Eisner MP, Kosary C, et al.: SEER Cancer Statistics Review, 1973–2001. Bethesda, MD: National Cancer Institute; 2004.Google Scholar
  2. 2.
    Mauch P, Kalish LA, Marcus KC, et al.: Long-term survival in Hodgkin’s disease: relative impact of mortality, second tumors, infection, and cardiovascular disease. Cancer J Sci Am 1995, 1:33–42.PubMedGoogle Scholar
  3. 3.
    van Leeuwen FE, Klokman WJ, Veer MB, et al.: Long-term risk of second malignancy in survivors of Hodgkin’s disease treated during adolescence or young adulthood. J Clin Oncol 2000, 18:487–497.PubMedGoogle Scholar
  4. 4.
    Bhatia S, Yasui Y, Robison LL, et al.: High risk of subsequent neoplasms continues with extended follow-up of childhood Hodgkin’s disease: report from the Late Effects Study Group. J Clin Oncol 2003, 21:4386–4394.PubMedCrossRefGoogle Scholar
  5. 5.
    Ng AK, Bernardo MV, Weller E, et al.: Second malignancy after Hodgkin disease treated with radiation therapy with or without chemotherapy: long-term risks and risk factors. Blood 2002, 100:1989–1996.PubMedCrossRefGoogle Scholar
  6. 6.
    Chronowski GM, Wilder RB, Levy LB, et al.: Second malignancies after chemotherapy and radiotherapy for Hodgkin disease. Am J Clin Oncol 2004, 27:73–80.PubMedCrossRefGoogle Scholar
  7. 7.
    Dores GM, Metayer C, Curtis RE, et al.: Second malignant neoplasms among long-term survivors of Hodgkin’s disease: a population-based evaluation over 25 years. J Clin Oncol 2002, 3484–3494.Google Scholar
  8. 8.
    van Leeuwen FE, Klokman WJ, Stovall M, et al.: Roles of radiation dose, chemotherapy, and hormonal factors in breast cancer following Hodgkin’s disease. J Natl Cancer Inst 2003, 95:971–980.PubMedCrossRefGoogle Scholar
  9. 9.
    Travis LB, Gospodarowicz M, Curtis RE, et al.: Lung cancer following chemotherapy and radiotherapy for Hodgkin’s disease. J Natl Cancer Inst 2002, 94:182–192.PubMedGoogle Scholar
  10. 10.
    Hancock SL, Tucker MA, Hoppe RT: Breast cancer after treatment of Hodgkin’s disease. J Natl Cancer Inst 1993, 85:25–31.PubMedCrossRefGoogle Scholar
  11. 11.
    Bhatia S, Robison LL, Oberlin O, et al.: Breast cancer and other second neoplasms after childhood Hodgkin’s disease. N Engl J Med 1996, 334:745–751.PubMedCrossRefGoogle Scholar
  12. 12.
    Travis LB, Hill D, Dores GM, et al.: Cumulative absolute breast cancer risk for young women treated for Hodgkin lymphoma. J Natl Cancer Inst 2005, 97:1428–1437.PubMedCrossRefGoogle Scholar
  13. 13.
    Kenney LB, Yasui Y, Inskip PD, et al.: Breast cancer after childhood cancer: a report from the Childhood Cancer Survivor Study. Ann Intern Med 2004, 141:590–597.PubMedGoogle Scholar
  14. 14.
    Aisenberg AC, Finkelstein DM, Doppke KP, et al.: High risk of breast carcinoma after irradiation of young women with Hodgkin’s disease. Cancer 1997, 79:1203–1210.PubMedCrossRefGoogle Scholar
  15. 15.
    Travis LB, Hill DA, Dores GM, et al.: Breast cancer following radiotherapy and chemotherapy among young women with Hodgkin disease. JAMA 2003, 290:465–475.PubMedCrossRefGoogle Scholar
  16. 16.
    Hill DA, Gilbert E, Dores GM, et al.: Breast cancer risk following radiotherapy for Hodgkin lymphoma: modification by other risk factors. Blood 2005, 106:3358–3365.PubMedCrossRefGoogle Scholar
  17. 17.
    Albrektsen G, Heuch I, Kvale G: The short-term and long-term effect of a pregnancy on breast cancer risk: a prospective study of 802,457 parous Norwegian women. Br J Cancer 1995, 72:480–484.PubMedGoogle Scholar
  18. 18.
    Adams MJ, Lipshultz SE: Pathophysiology of anthracycline-and radiation-associated cardiomyopathies: implications for screening and prevention. Pediatr Blood Cancer 2005, 44:600–606.PubMedCrossRefGoogle Scholar
  19. 19.
    Hancock SL, Hoppe RT: Long-term complications of treatment and causes of mortality after Hodgkin’s disease. Semin Radiat Oncol 1996, 6:225–242.CrossRefPubMedGoogle Scholar
  20. 20.
    Aleman BM, van den Belt-Dusebout AW, Klokman WJ, et al.: Long-term cause-specific mortality of patients treated for Hodgkin’s disease. J Clin Oncol 2003, 21:3431–3439.PubMedCrossRefGoogle Scholar
  21. 21.
    Aleman BM, van den Belt-Dusebout AW, De Bruin ML, et al.: Late cardiotoxicity after treatment for Hodgkin lymphoma. Blood 2007, 109:1878–1886.PubMedCrossRefGoogle Scholar
  22. 22.
    Lee CK, Aeppli D, Nierengarten ME: The need for long-term surveillance for patients treated with curative radiotherapy for Hodgkin’s disease: University of Minnesota experience. Int J Radiat Oncol Biol Phys 2000, 48:169–179.PubMedCrossRefGoogle Scholar
  23. 23.
    Hancock SL, Tucker MA, Hoppe RT: Factors affecting late mortality from heart disease after treatment of Hodgkin’s disease. JAMA 1993, 270:1949–1955.PubMedCrossRefGoogle Scholar
  24. 24.
    Hancock SL, Donaldson SS, Hoppe RT: Cardiac disease following treatment of Hodgkin’s disease in children and adolescents. J Clin Oncol 1993, 11:1208–1215.PubMedGoogle Scholar
  25. 25.
    Reinders JG, Heijmen BJ, Olofsen-van Acht MJ, et al.: Ischemic heart disease after mantlefield irradiation for Hodgkin’s disease in long-term follow-up. Radiother Oncol 1999, 51:35–42.PubMedCrossRefGoogle Scholar
  26. 26.
    Boivin J-F, Hutchison G, Lubin J, Mauch P: Coronary artery disease mortality in patients treated for Hodgkin’s disease. Cancer 1992, 69:1241–1247.PubMedCrossRefGoogle Scholar
  27. 27.
    Heidenreich PA, Schnittger I, Strauss HW, et al.: Screening for coronary artery disease after mediastinal irradiation for Hodgkin’s disease. J Clin Oncol 2007, 25:43–49.PubMedCrossRefGoogle Scholar
  28. 28.
    Adams MJ, Lipsitz SR, Colan SD, et al.: Cardiovascular status in long-term survivors of Hodgkin’s disease treated with chest radiotherapy. J Clin Oncol 2004, 22:3139–3148.PubMedCrossRefGoogle Scholar
  29. 29.
    Heidenreich PA, Hancock SL, Vagelos RH, et al.: Diastolic dysfunction after mediastinal irradiation. Am Heart J 2005, 150:977–982.PubMedCrossRefGoogle Scholar
  30. 30.
    Iarussi D, Pisacane C, Indolfi P, et al.: Evaluation of left ventricular function in long-term survivors of childhood Hodgkin disease. Pediatr Blood Cancer 2005, 45:700–705.PubMedCrossRefGoogle Scholar
  31. 31.
    Swerdlow AJ, Higgins CD, Smith P, et al.: Myocardial infarction mortality risk after treatment for Hodgkin disease: a collaborative British cohort study. J Natl Cancer Inst 2007, 99:206–214.PubMedCrossRefGoogle Scholar
  32. 32.
    Bowers DC, McNeil DE, Liu Y, et al.: Stroke as a late treatment effect of Hodgkin’s disease: a report from the Childhood Cancer Survivor Study. J Clin Oncol 2005, 23:6508–6515.PubMedCrossRefGoogle Scholar
  33. 33.
    Bilora F, Pietrogrande F, Petrobelli F, et al.: Is radiation a risk factor for atherosclerosis? An echo-color Doppler study on Hodgkin and non-Hodgkin patients. Tumori 2006, 92:295–298.PubMedGoogle Scholar
  34. 34.
    Horning SJ, Adhikari A, Rizk N, et al.: Effect of treatment for Hodgkin’s disease on pulmonary function: results of a prospective study. J Clin Oncol 1994, 12:297–305.PubMedGoogle Scholar
  35. 35.
    Friedman DL, Constine LS: Late effects of treatment for Hodgkin lymphoma. J Natl Comp Cancer Netw 2006, 4:249–257.Google Scholar
  36. 36.
    Martin WG, Ristow KM, Habermann TM, et al.: Bleomycin pulmonary toxicity has a negative impact on the outcome of patients with Hodgkin’s lymphoma. J Clin Oncol 2005, 23:7614–7620.PubMedCrossRefGoogle Scholar
  37. 37.
    Knobel H, Havard LJ, Brit LM, et al.: Late medical complications and fatigue in Hodgkin’s disease survivors. J Clin Oncol 2001, 19:3226–3233.PubMedGoogle Scholar
  38. 38.
    Sklar C, Whitton J, Mertens A, et al.: Abnormalities of the thyroid in survivors of Hodgkin’s disease: data from the Childhood Cancer Survivor Study. J Clin Endocrinol Metab 2000, 85:3227–3232.PubMedCrossRefGoogle Scholar
  39. 39.
    Metzger ML, Hudson MM, Somes GW, et al.: White race as a risk factor for hypothyroidism after treatment for pediatric Hodgkin’s lymphoma. J Clin Oncol 2006, 24:1516–1521.PubMedCrossRefGoogle Scholar
  40. 40.
    Sklar CA, Mertens AC, Mitby P, et al.: Premature menopause in survivors of childhood cancer: a report from the Childhood Cancer Survivor Study. J Natl Cancer Inst 2006, 98:890–896.PubMedCrossRefGoogle Scholar
  41. 41.
    Chemaitilly W, Mertens AC, Mitby P, et al.: Acute ovarian failure in the Childhood Cancer Survivor Study. J Clin Endocrinol Metab 2006, 91:1723–1728.PubMedCrossRefGoogle Scholar
  42. 42.
    Behringer K, Breuer K, Reineke T, et al.: Secondary amenorrhea after Hodgkin’s lymphoma is influenced by age at treatment, stage of disease, chemotherapy regimen, and the use of oral contraceptives during therapy: a report from the German Hodgkin’s Lymphoma Study Group. J Clin Oncol 2005, 23:7555–7564.PubMedCrossRefGoogle Scholar
  43. 43.
    Loge JH, Abrahamsen AF, Ekeberg O, Kaasa S: Hodgkin’s disease survivors more fatigued than the general population. J Clin Oncol 1999, 17:253–261.PubMedGoogle Scholar
  44. 44.
    Mols F, Vingerhoets AJ, Coebergh JW, et al.: Better quality of life among 10–15 year survivors of Hodgkin’s lymphoma compared to 5–9 year survivors: a population-based study. Eur J Cancer 2006, 42:2794–2801.PubMedCrossRefGoogle Scholar
  45. 45.
    Hjermstad MJ, Fossa SD, Oldervoll L, et al.: Fatigue in long-term Hodgkin’s disease survivors: a follow-up study. J Clin Oncol 2005, 23:6587–6595.PubMedCrossRefGoogle Scholar
  46. 46.
    Hjermstad MJ, Oldervoll L, Fossa SD, et al.: Quality of life in long-term Hodgkin’s disease survivors with chronic fatigue. Eur J Cancer 2006, 42:327–333.PubMedCrossRefGoogle Scholar
  47. 47.
    Ng AK, Li S, Recklitis C, et al.: A comparison between long-term survivors of Hodgkin’s disease and their siblings on fatigue level and factors predicting for increased fatigue. Ann Oncol 2005, 16:1949–1955.PubMedCrossRefGoogle Scholar
  48. 48.
    Donaldson SS, Link MP, Weinstein HJ, et al.: Final results of a prospective clinical trial with VAMP and low-dose involved-field radiation for children with low-risk Hodgkin’s disease. J Clin Oncol 2007, 25:332–337.PubMedCrossRefGoogle Scholar
  49. 49.
    Chow LM, Nathan PC, Hodgson DC, et al.: Survival and late effects in children with Hodgkin’s lymphoma treated with MOPP/ABV and low-dose, extended-field irradiation. J Clin Oncol 2006, 24:5735–5741.PubMedCrossRefGoogle Scholar
  50. 50.
    Children’s Oncology Group: Long-term follow-up guidelines for survivors of childhood, adolescent, and young adult cancers (Ver. 2.0, 2006). http://www.survivorshipguidelines.org/. Accessed March 2007.
  51. 51.
    Saslow D, Boetes C, Burke W, et al.: American Cancer Society guidelines for breast screening with MRI as an adjunct to mammography. CA Cancer J Clin 2007, 57:75–89.PubMedCrossRefGoogle Scholar
  52. 52.
    Expert Panel on Detection Evaluation and Treatment of High Blood Cholesterol In Adults: Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA 2001, 285:2486–2497.CrossRefGoogle Scholar

Copyright information

© Current Medicine Group LLC 2007

Authors and Affiliations

  • Michael Jacob Adams
  • Louis S. Constine
  • Steven E. Lipshultz
    • 1
  1. 1.Department of PediatricsUniversity of Miami Miller School of MedicineMiamiUSA

Personalised recommendations